FOXK1 regulates malignant progression and radiosensitivity through direct transcriptional activation of CDC25A and CDK4 in esophageal squamous cell carcinoma

doi:10.21203/rs.3.rs-2368026/v1

Download PDF

Article

FOXK1 regulates malignant progression and radiosensitivity through direct transcriptional activation of CDC25A and CDK4 in esophageal squamous cell carcinoma

https://doi.org/10.21203/rs.3.rs-2368026/v1

This work is licensed under a CC BY 4.0 License

Journal Publication

published 12 May, 2023

Read the published version in Scientific Reports →

You are reading this latest preprint version

The transcription factor forkhead box K1 (FOXK1) has recently been recognized to mediate a wide range of biological progresses, including cell proliferation, differentiation, cell cycle progression, apoptosis, DNA damage, and tumorigenesis. However, the role and molecular mechanisms of FOXK1 in esophageal squamous cell carcinoma (ESCC) progression and in the response to ionizing radiation (IR) have not been well characterized. In this study, we investigated the expression level, clinical significance, biological role, and molecular mechanism of FOXK1 in ESCC. High expression level of FOXK1 was observed in ESCC cell lines and tissues, which was correlated with TNM stage, invasion depth, and lymph node metastasis. In addition, overexpression of FOXK1 promoted ESCC cells proliferation, migration, and invasion, whereas silencing FOXK1 showed the opposite effect. Moreover, Silencing FOXK1 enhanced radiosensitivity by inhibiting DNA damage repair, inducing G1 arrest and apoptosis. Further studies revealed that FOXK1 activated transcription of CDC25A and CDK4 in ESCC cells by directly binding to their promoter regions. Furthermore, knockdown of CDC25A or CDK4 reversed those biological processes mediated by overexpression of FOXK1. Collectively, FOXK1, as well as its downstream target genes CDC25A and CDK4, may be potential therapeutic and radiosensitizing targets for ESCC.

Biological sciences/Cancer/Gastrointestinal cancer/Oesophageal cancer

Biological sciences/Cancer/Oncogenes

Biological sciences/Cancer/Cancer therapy/Radiotherapy

esophageal squamous cell carcinoma

FOXK1

CDC25A

CDK4

Esophageal cancer is the seventh most common cancer worldwide and the sixth leading cause of cancer-related mortality ¹. There are two main histological subtypes: esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma, with ESCC being the predominant type and having high morbidity and familial clustering in northern China ^2,3. The aggressive nature of ESCC with early loco-regional spread often leads to an advanced stage and poor prognosis. The standard therapies for patients with locally advanced disease is to receive definitive chemoradiation therapy (CRT) or neoadjuvant CRT followed by surgery. For advanced cases, CRT is the standard of care when surgery is not applicable. Although aggressive multimodal therapy has improved long-term survival in patients with locally advanced ESCC, the rate of local recurrence after CRT remains dismal ^4,5. In the era of precision medicine and molecularly targeted therapies, understanding the molecular drivers of tumorigenesis and radioresistance, and thus developing promising diagnostic and therapeutic strategies in ESCC remain a critical unmet clinical need.

FOX proteins are a superfamily of evolutionarily conserved transcriptional regulators that control a wide spectrum of biological processes ⁶. As an important member of the FOX family, FOXK1 is also involved in the regulation of a variety of biological processes, including cell proliferation, differentiation, cell cycle progression, autophagy, glycolysis, and DNA damage response ^7–12. In addition, FOXK1 has been found to be upregulated in many malignant tissues and induces tumor proliferation and metastasis ^13–16. In particular, FOXK1 has been shown to promote proliferation and invasion of ESCC cells ¹⁷. Nevertheless, the downstream target genes of FOXK1 and the mechanisms behind its oncogenic effects remain largely unknown. Also, these evidences of FOXK1 in regulating cell cycle progression and DNA damage response suggest its possible roles in radiosensitivity and need to be clarified.

In order to verify the biological effects and mechanism of FOXK1 in ESCC, in the present study, we assessed the expression of FOXK1 in ESCC cell lines and tissues, examined its function in regulating oncogenesis and radiosensitivity in ESCC cells, and analyzed the target genes of FOXK1 and their roles in mediating ESCC progression and response to radiation.

Increased expression of FOXK1 in ESCC cell lines and tissues. The mRNA and protein expression levels of FOXK1 were significantly upregulated in four ESCC cells compared with normal esophageal epithelial cell, detected by qRT-PCR and western blot assays (Fig. 1a, 1b). Upregulation of FOXK1 was also observed in ESCC tissues compared to corresponding adjacent normal tissues (P < 0.05) (Fig. 1c), and the same expression trend could be observed in Oncomine database (Fig. 1d). According to the clinicopathological features, high expression level of FOXK1 (the expression level of FOXK1 in tumor tissues was higher than that in corresponding normal tissues by 200%) was associated with TNM stage, invasion depth, and lymph node metastasis (Supplementary Table 1).

Association between expression of FOXK1 and survival of ESCC patients. The impact of FOXK1 on the prognosis of ESCC patients was further evaluated. ESCC patients with low expression level of FOXK1 (34/105, 32.4%) was associated with better survival when compared to that with high expression level of FOXK1 (71/105, 67.6%) (P = 0.001) (Fig. 1e). The 5-year survival rate for patients expressing high levels of FOXK1 was 13.3% (median survival time, 23.2 months), while those with low expression levels of FOXK1 was 27.6% (median survival time, 43.2 months) (P = 0.001). A comprehensive analysis of the effects of clinical stage and FOXK1 expression on patients' prognosis revealed that stage III and IV patients with high expression level of FOXK1 had poorer survival rates (Fig. 1f). Patients with stage I + II and stage III + IV were analyzed separately, and the patients with high expression level of FOXK1 had significantly lower survival times than those with low expression level of FOXK1 (P < 0.05), no matter in stage I + II or stage III + IV (Fig. 1g, 1h). In addition, based on the results of univariate analysis, the significant prognostic factors for survival of ESCC patients were TNM stage (P < 0.001), depth of invasion (P < 0.001), lymph node metastasis (P = 0.005), distant metastasis (P < 0.001), and FOXK1 expression (P = 0.001). Results of multivariate analysis showed that depth of invasion (P < 0.001), lymph node metastasis (P = 0.045), distant metastasis (P < 0.001), and FOXK1 expression (P = 0.003) were independently associated with ESCC patients' survival (Supplementary Table 2).

FOXK1 promotes ESCC cells proliferation, migration, and invasion in vitro. We further investigated the biological functions of FOXK1 in ESCC cells. Considering the expression level of FOXK1 in ESCC cell lines, the pcDNA3.1-FOXK1 plasmid was used to overexpress FOXK1 in KYSE170 and TE1 cells, and siRNA (si-FOXK1) was used to knockdown FOXK1 in KYSE150 and TE1 cells. The transfection efficiency was verified by qRT-PCR and Western blot assays (Fig. 2a, Supplementary Fig. 1a). Overexpression of FOXK1 enhanced the proliferation, migration, and invasion ability of KYSE170 and TE1 cells (Fig. 2b-2e, Supplementary Fig. 1b-1e). In contrast, knockdown of FOXK1 significantly inhibited proliferation, migration, and invasion ability of KYSE150 and TE1 cells (Fig. 2b-2e, Supplementary Fig. 1b-1e).

Overexpression of FOXK1 confers radioresistance and regulates the phosphorylation of H2AX after irradiation. We next analyzed whether FOXK1 affected the radiosensitivity of ESCC cells. The expression level of FOXK1 was significantly upregulated in pcDNA3.1-FOXK1 stably transfected KYSE170 and TE1 cells (Fig. 3a). According to results of colony formation assays, cells with upregulated FOXK1 showed increased clonal survival after radiation exposure, and their survival curves showed higher D0, N, and Dq values (P < 0.05), indicating that overexpression of FOXK1 conferred radioresistance (Fig. 3b, Supplementary Table 3). The cell viability of FOXK1 overexpressing ESCC cells after irradiation was also significantly higher than that of the corresponding control cells (Fig. 3c). We next assessed whether FOXK1 was involved in radiation-induced DNA damage repair. ESCC cells were treated with graded doses of radiation (0–10 Gy) and incubated for 3 h before harvesting. As shown in Fig. 3d, IR activated expression of FOXK1 and γH2AX in a dose-dependent manner in KYSE170 and TE1 cells. To discern the time course of induction of FOXK1 and γH2AX after irradiation, the cells were exposed to 8 Gy radiation and harvested after different time intervals. Induction of FOXK1 and γH2AX was significantly increased in cells harvested after irradiation within 1 h, and their protein levels reached a maximum at 2 h, and then started declining gradually after 4 h (Fig. 3e). Subsequently, we exposed FOXK1 knockdown KYSE170 and TE1 cells to radiation to test the expression of γH2AX. As displayed in Fig. 3f, downregulating FOXK1 significantly inhibited the activation of γH2AX after irradiation. These results suggested an important role for FOXK1 in conferring radioresistance in ESCC.

Effect of knockdown of FOXK1 on cell cycle and apoptosis after irradiation of esophageal cancer cells. Further investigations were conducted to determine if FOXK1 inhibited radiosensitivity through cell cycle redistribution and apoptosis. Knockdown of FOXK1 resulted in G1 arrest in KYSE150 and TE1 cells, whereas cells with knockdown of FOXK1 exhibited more pronounced G1 arrest after irradiation (Fig. 4a). Silencing FOXK1 also induced apoptosis and this effect was augmented by radiation exposure (Fig. 4b). Western blot analysis of cell cycle and apoptosis related proteins showed that cyclin D1, CDK4, and Bcl-2 were downregulated in FOXK1 knockdown cells, while p21 and Bax were upregulated; and these trends were more drastic in irradiated FOXK1 knockdown cells (Fig. 4c). These above findings demonstrated that the radiosensitizing effect of FOXK1 knockdown was contributed to G1 arrest and apoptosis.

FOXK1 increases the transcription of CDC25A and CDK4 by directly binding to their promoters. FOXK1 binding motif was retrieved from JASPAR ¹⁸ (Fig. 5a). A set of proliferation-related genes containing this motif in their promoter regions were screened, including CCND3, CCNE2, CDC7, CDC20, CDC23, CDC25A, CDC25C, CDK1, CDK4, FGF12, FGFR2, FGFR4, NOTCH1, AKT2, BMP6, BMP7, ROCK1, TGFB1, TGFBR2, VEGFA, PDGFRA, DVL2, DVL3, FZD1, FZD3, and FZD6. Among these genes, CCNE2, CDC25A, CDK4, AKT2, and FZD3 demonstrated an increase trend in FOXK1 overexpressed KYSE170 and TE1 cells, and a decrease trend in FOXK1 knockdown KYSE150 and TE1 cells (Supplementary Fig. 2a, 2b). Among them, we focused on CDC25A and CDK4, which were involved in tumor growth and radiosensitivity ^19–22. As shown in Fig. 5b, two putative FOXK1 binding sites were respectively identified around the TSS regions of CDC25A and CDK4. Overexpression of FOXK1 increased the mRNA and protein expression levels of CDC25A and CDK4, whereas silencing FOXK1 suppressed their expression (Fig. 5c, 5d). The expression levels of CDC25A and CDK4 in ESCC tissues were also positively correlated with FOXK1 (Fig. 5e), and similar trends could be observed in the Oncomine database (Fig. 5f).

Next, a series of deletion constructs of the CDC25A and CDK4 promoters were subcloned into the pGL3-Basic vector. As shown in Fig. 5g, the plasmids pCDC25A-1802/+76 and pCDC25A-961/+76 exhibited higher luciferase activity in FOXK1 overexpressing KYSE170 cells, whereas the pCDC25A-590/+76 showed almost no luciferase activity. To identify the specific binding site, we mutated site 1 (-907 bp to -900 bp) and site 2 (-1757 bp to -1750bp) separately. The luciferase activity showed a significant decrease when site 1 was mutated, while mutation at site 2 showed no marked change, indicating the critical role of site 1. For the CDK4 promoter, the deletion constructs pCDK4-1328/+22 and pCDK4-865/+22 displayed substantially increased luciferase activity in FOXK1 overexpressing KYSE170 cells, however, the FOXK1-dependent luciferase activity failed to elevate in pCDK4-511/+22. Moreover, only mutation in site 1 (-704 bp to -697 bp) decreased the luciferase activity, indicating that this may be the binding site for FOXK1 to CDK4 promoter (Fig. 5h). Further ChIP assays confirmed the enrichment of FOXK1 at site 1 of the CDC25A promoter and also at site 1 of the CDK4 promoter (Fig. 5i, 5j). These results collectively suggested that the elevated expression of CDC25A and CDK4 in ESCC might be partly due to the transcriptional regulation of FOXK1.

Overexpression of FOXK1 enhances ESCC cells growth, migration, and invasion through regulation of CDC25A and CDK4. To verify whether FOXK1 exerted oncogenic effects in ESCC cells by controlling the transcription of CDC25A and CDK4, we further performed rescue experiments by knocking down CDC25A and CDK4, respectively, in FOXK1 overexpressing KYSE170 and TE1 cells. As shown in Fig. 6a-6d and Supplementary Fig. 3a-3d, reduction of CDC25A partially reversed the enhanced proliferation, migration, and invasion ability induced by overexpression of FOXK1. As illustrated in Fig. 7a-7d and Supplementary Fig. 4a-4d, silencing CDK4 also attenuated the role of FOXK1 in promoting ESCC cells proliferation, migration, and invasion. In addition, knockdown of CDC25A in parallel with knockdown of CDK4 resulted in a more pronounced offsetting effect (Fig. 7a-7d, Supplementary Fig. 4a-4d). Together, it can be concluded that FOXK1 played an oncogenic role in ESCC by transcriptional activation of CDC25A and CDK4.

Overexpression of FOXK1 confers radioresistance by activating CDC25A and CDK4 in ESCC cells. To further validate the involvement of CDC25A and CDK4 in FOXK1-regulated radiosensitivity of ESCC cells, rescue experiments were performed. The survival fraction of KYSE170 and TE1 cells gradually decreased with increasing radiation dose, while FOXK1 overexpressing cells exhibited relatively higher clonal survival. However, knockdown of CDC25A inhibited this proliferative capacity of FOXK1 (Fig. 8a). By assessing cell viability at different time points after irradiation, the cell viability of FOXK1 overexpressing cells was significantly increased compared to the corresponding control cells; while downregulation of CDC25A suppressed the increase in viability induced by FOXK1 (Fig. 8b). Similarly, CDK4 deficiency attenuated the clonal proliferation capacity of FOXK1 overexpressing cells after graded doses of radiation. This FOXK1-induced proliferation ability was more severely impaired by the concurrent downregulation of CDK4 and CDC25A (Fig. 8c). Silencing CDK4 also made FOXK1 overexpressing ESCC cells less capable of proliferation at different time points after irradiation. Moreover, this reversal effect was more prominent when both CDK4 and CDC25A were silenced (Fig. 8d). These results supported that FOXK1-mediated radioresistance of ESCC cells might be dependent on its transcriptional regulation of CDC25A and CDK4.

The FOX proteins play pleiotropic roles in biological processes and their dysfunction is associated with tumorigenesis and cancer progression ^6,23. FOXK1, an important member of the FOX family, is located at chromosomal position 7p22. FOXK1 has been proved to play an oncogenic role in a variety of cancers; however, its role and molecular mechanisms in the progression and radiosensitivity of esophageal cancer are not well clarified. In the present study, upregulation of FOXK1 was detected in ESCC cells and tissues, which was associated with tumor stage and poor prognosis. In addition, FOXK1 enhanced proliferation, migration, invasion, and radiation resistance of ESCC cells through transcriptional upregulation of CDC25A and CDK4.

Upregulation of FOXK1 has been detected in several types of human cancers including gastric, gallbladder, and colorectal cancers, and high expression of FOXK1 may lead to poor prognosis in different types of cancers ^14,16,24. Previous study has shown elevated expression of FOXK1 in ESCC tissues, which affects the survival of ESCC patients ¹⁷. Our and Chen’s study ¹⁷ also demonstrated the promoting effects of FOXK1 on ESCC cells proliferation, migration, and invasion, which was consistent with the studies in hepatocellular carcinoma, gastric cancer, colorectal cancer, and gallbladder cancer ^{14–16, 25}. These results suggest that FOXK1 may play an oncogenic role in multiple malignancies, including ESCC.

Studies have shown that FOXK1 has a role in suppressing DNA damage repair ¹², that inspired us to investigate its effect in radiosensitivity. Our results suggested that FOXK1 conferred radioresistance to ESCC cells. IR is known to induce cell death mainly by causing DNA double-strand breaks (DSBs). The early cellular response to DSBs is C-terminal phosphorylation of H2AX (termed γH2AX), and subsequently γH2AX serves as a platform to recruit other DNA repair proteins to the site of DSBs ^26,27. Therefore, γH2AX is widely used as a marker in detecting radiation-induced DSBs repair ^28,29. In the present study, FOXK1 promoted the activation of γH2AX after irradiation, suggesting FOXK1 may confer radioresistance by inducing DNA damage repair. In addition, IR exposure causes cells to arrest in G1 and G2 phases, and cells possessing G1 arrest are more sensitive to IR ^30,31. Consistent with these reports, our observation of FOXK1 deficiency promoting G1 arrest in irradiated cells suggests its role in radiosensitivity. Targeting FOXK1 may be a useful adjunct to radiation therapy in the treatment of ESCC.

To further elucidate the molecular mechanism of FOXK1, we identified two novel FOXK1 target genes in ESSC: CDC25A and CDK4. CDC25A is a member of the CDC25 family of phosphatases. It mainly activates CDK2 and thereby induces progression in the cell cycle from G1 to S phase ³². The upregulation of CDC25A in a variety of tumors and its oncogenic role have been widely reported ^33,34. CDC25A has also been shown to modulate radiosensitivity in esophageal, cervical, and lung cancers ^20,35,36. Another FOXK1 target gene, CDK4, is a catalytic subunit of the protein kinase complex that plays a critical role in the G1-S checkpoint ³⁷. CDK4 has functions in promoting proliferation, migration, invasion, and angiogenesis in various cancers ^21,38. Moreover, CDK4/6 inhibitors have had great success in treating certain cancer types, such as breast and lung cancer, and are in clinical trials for many other tumors ^39–41. As silencing CDK4 resulted in blockade of cell cycle progression, enhancement of apoptosis, and suppressing DNA damage repair, CDK4 has recently been proved to be a novel target for radiosensitization ^42–44. Particularly, several preclinical studies have validated the radiosensitization effects of CDK4/6 inhibitors in vitro and in vivo ^45,46. Our study is consistent with these findings and suggests a critical role for both CDC25A and CDK4 in oncogenicity and radioresistance of ESCC cells, which is transcriptionally controlled by FOXK1.

In conclusion, our study revealed the upregulation of FOXK1 in ESCC and its adverse effect on prognosis. FOXK1 exerts oncogenic and radioresistant role through transcriptional activation of CDC25A and CDK4. FOXK1 may be act as a promising biomarker and a novel therapeutic target for ESCC.

Patients and tissue specimens. A total of 105 cases of ESCC tissues and paired adjacent non-tumor tissues were obtained from patients admitted to the Fourth Hospital of Hebei Medical University between 2012 and 2016 with a confirmed diagnosis of ESCC who received surgical resection as their first treatment. Each surgically excised specimen was placed in liquid nitrogen immediately after acquisition and stored at -80°C for RNA extraction. Treatment records, clinical history, and follow-up data of patients were retrieved from the case management system in the medical record room. Grading and staging were undertaken according to the 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction. A positive family history of upper gastrointestinal cancer (UGIC) was defined as a self-reported history of esophageal/cardia/gastric cancer in at least one of the first-degree relatives or two second-degree relatives. Written informed consent was obtained from all patients, and the study was approved by the Ethics Committee of the Fourth Hospital of Hebei Medical University.

Cell culture and X‑ray irradiation. Human esophageal cancer cell lines KYSE170, TE1, KYSE150, KYSE109 and human normal esophageal epithelial cell line HEEpiC were purchased from China Center for Type Culture Collection (CCTCC, Wuhan, China). The ESCC cell lines were cultured in RPMI 1640 (Gibco, Invitrogen, Life Technologies, Germany) medium supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA) at 37°C with 5% CO₂. The HEEpiC cells were cultured according to the manufacturer’s instructions.

Irradiation was performed at room temperature with a 6-MV Varian linear accelerator (Varian Medical Systems, Palo Alto, CA, USA) at a dose rate of 5 Gy/min and a source-skin distance of 100 cm. After irradiation, cells were recovered in respective growth medium for the indicated time until harvesting.

RNA isolation and quantitative real-time polymerase chain reaction (qRT-PCR) assay. Total RNA was isolated from tissue samples and cell lines using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and the RNA was reverse transcribed into cDNA with Transcriptor First Strand cDNA Synthesis Kit (Roche, Basel, Switzerland) according to the manufacturer’s instruction. The qRT-PCR was performed in triplicate with StepOnePlus Real-Time PCR System (Applied Biosystems) using GoTap® qPCRMaster Mix (Promega, Madison, WI, USA). Expression of genes was normalized to the expression of GAPDH. Data were analyzed and showed with 2^−ΔΔCt method. All primers used for qRT-PCRs were listed in Supplementary Table 4.

Cell transfection. FOXK1 siRNAs, CDK4 siRNAs, and CDC25A siRNAs were purchased from Ribbio (Guangzhou, China). The siRNA sequences were shown in Supplementary Table 5. For overexpression of FOXK1, CDK4, and CDC25A, the cDNAs encoding them were PCR-amplified and subcloned into pcDNA3.1 vector (Invitrogen, Carlsbad, CA, USA). For transient transfections, Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA) was used according to the manufacturer’s instructions. The cells were collected after transfection with siRNA oligonucleotides (100 nM) or plasmids (2 mg) for 48 h. The infection efficiency was validated using qRT-PCR or western blotting assays. To generate FOXK1 stably expressing cells, the cells were isolated using 800 µg/mL of G418 after transient transfection.

Western blotting assay. Total protein extraction was performed in RIPA lysis buffer with PMSF (Solarbio, Beijing, China). Protein concentration was determined using BCA Protein Assay (Multi Sciences, Hangzhou, China). Equal amounts of protein samples were electrophoresed on 10% sodium dodecyl sulfate-polyacrylamide electrophoresis gel and then transferred onto polyvinylidene fluoride membranes (Millipore, Billerica, MA, USA), followed by blocking with 5% skim milk for an hour. Afterwards, the membranes were probed with specific primary antibodies overnight at 4°C and then with secondary antibody (KPL, Milford, MA, USA) for an hour at room temperature. The primary antibodies used were listed in Supplementary Table 6. Then the signals were visualized using enhanced chemiluminescence reagent (Multi Sciences, Hangzhou, China).

Cell viability assay. Cell viability was assessed using an MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2‐(4‐sulfophenyl)‐2H‐tetrazolium) assay. A CellTiter 96® Aqueous One Solution Cell Proliferation Assay kit (Promega, Madison, WI, USA) was used according to the manufacturer's instructions. The transfected cells were seeded at 1×10³ cells/well and cultured in 96‐well plates. MTS reagent (20 µl) was added to 100 µl culture medium at different time points and incubated for 2 h. Then, the cell content was calculated by detecting the absorbance of each well at 490 nm via a Spark® multimode microplate reader (Tecan).

For cell viability after irradiation, cells were plated in 96-well plates to a density of 5×10³ cells/ml and incubated for 24 h at 37°C. The viability of cells irradiated at 8 Gy was determined by incubation with MTS reagent, same as above.

Colony formation assay. The 5×10³ transfected cells were inoculated in triplicate in 6-well plates and cultured for approximately 7 days until colonies were visible. The colonies (containing 50 cells or more) were counted manually after fixed with 4% paraformaldehyde and stained with 0.1% crystal violet.

For colony formation assay after irradiation, cells stably expressing FOXK1 and their respective control cells were plated at a low density onto 6-well plates (500 cells/well), followed by graded single doses (0–8 Gy). Two weeks later, the cells were fixed and stained with crystal violet (0.6%). Colonies of ≥ 50 cells were scored as survivors. The mean survival data for each individual cell line were fitted to the linear quadratic (LQ) model: SF = 1-(1-e^− D/D0)^N, where SF is the survival fraction, D is the irradiation dose, D0 is the mean lethal dose, and N is the extrapolation number.

Wound-healing assay. Cell migration capacities were evaluated by wound healing assays. The transfected cells were seeded into 6-well plates until grown to confluence. A scratch wound was generated using a sterile 200-µL pipette tip, and floating cells were removed by washing with 1 × PBS. Migration was photographed at the indicated time points after scratching using an inverted microscope and the percent wound closure was calculated for 3 randomly chosen fields.

Cell invasion assay. Cell migration assays were performed in Matrigel-coated chambers (Corning Costar, Corning, NY, USA) with 8-µm pore membranes. The 1×10⁵ transfected cells suspended in 200 µL of serum-free RPMI 1640 medium were added to the upper chamber while the lower compartment of the chamber was filled with 600 µL of the medium containing 10% FBS. After 24 h of incubation at 37°C, the non-migrating cells in the upper chamber were removed by a cotton swab and lower surface of the chamber was fixed with 4% paraformaldehyde and stained with crystal violet. Invading cells were scored by counting at least 5 fields per membrane under a light microscope.

Flow cytometry analysis of cell cycle and apoptosis. FITC Annexin V and propidium iodide (PI) (BD bioscience, CA, USA) double staining was used to detect cell apoptosis, and PI (Multi Science, Hangzhou, China) mono staining was applied to monitor cell cycle. After the transfected cells (with or without 8 Gy single-dose of irradiation) were harvested, the cell concentration was adjusted to 1 × 10⁶ cells per ml and then washed twice with PBS. Thereafter, apoptosis was detected by adding 5 µl of FITC Annexin V and 5 µl of PI to 100 µl cell solution for staining in the dark at room temperature for 15 min. To detect cell cycle, the cells were stained with 500 µl PI (1 µg/ml) for 30 min at room temperature in the dark. Flow cytometer was used to detect cell apoptosis and cell cycle.

Dual-luciferase reporter assays. The CDC25A promoter construct was obtained from PCR amplified fragment from genomic DNA and was cloned into the pGL3-Basic vector. The KYSE170 cells overexpressing FOXK1 or KYSE150 cells with knockdown of FOXK1 and their respective control transfectants were plated at a density of 1 × 10⁵ − 5 × 10⁵ cells/mL into 24-well plates and transfected with 0.2 µg pGL3-CDC25A promoter luciferase plasmid and 0.02 µg SV40 Renilla luciferase plasmid. After 48 h, firefly and Renilla luciferase activities were assayed sequentially in each well by Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA). Transcriptional activity was calculated as the ratio of firefly luciferase activity (reporter) to Renilla luciferase activity (control). All luciferase assays were carried out in triplicate. The CDK4 promoter construct was generated similarly and conducted the dual-luciferase reporter assays as described above. The primers of a series of CDC25A and CDK4 promoter fragments are listed in Supplementary Table 7.

Chromatin immunoprecipitation (ChIP) assay. ChIP assay was performed using EZ-Magna ChIP A/G (17-10086, Upstate, Millipore, MA, USA) kit to study the enrichment of FOXK1 in CDK4 and CDC25A promoter regions according to the manufacturer’s instructions. Antibody against FOXK1 (ab85999; Abcam) was used for immunoprecipitation. Quantitative analysis of ChIP-derived DNA was performed by real-time qPCR analysis (primers in Supplementary Table 7).

Statistical analysis. Statistical analyses were conducted with GraphPad Prism 8.0 and SPSS 25.0. Student’s t-test or Pearson's χ² test was used to determine statistical significance. Error bars show mean ± standard deviation (SD) of independent experiments. All tests were performed two-tailed and P values < 0.05 were considered statistically significant. Kaplan-Meier analyses were used for overall survival curves and P values were calculated with the log-rank test. Uni-/multivariate analyses were computed by Cox proportional hazards model. Spearman r correlation analysis was applied to calculate bivariate correlations among the study variables.

Ethics Declarations

Ethics declarations

All methods in this research were performed in accordance with the principles of the Declaration of Helsinki. The study was approved by the Ethics Committee of the Fourth Hospital of Hebei Medical University.

Acknowledgements

This study was supported by Grants from the National Natural Science Foundation of China (No. 81772612, No. 82203622), Natural Science Foundation of Hebei Province (No. H2020206363, No. H2021206259).

Author contributions

GW designed and conceptualized the research framework. LXX and LJT performed the majority of the experiments, analyzed and interpreted the data. XTX, CLY, YZY and LY assisted in the experiments. LL and LF collected patient samples. GW and LXX edited and revised the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare no competing interests.

Data availability

The data generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 71, 209-249 (2021).
Kamangar, F., Dores, G. M. & Anderson, W. F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 24, 2137-2150 (2006).
Guohong, Z. et al. Genetic heterogeneity of oesophageal cancer in high-incidence areas of southern and northern China. PLoS One. 5, e9668 (2010).
Ishihara, R. et al. Factors predictive of tumor recurrence and survival after initial complete response of esophageal squamous cell carcinoma to definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys. 76, 123-129 (2010).
Pennathur, A., Gibson, M. K., Jobe, B. A. & Luketich, J. D. Oesophageal carcinoma. Lancet. 381, 400-412 (2013).
Myatt, S. S. & Lam, E. W. The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 7, 847-859 (2007).
Shi, X. et al. Foxk1 promotes cell proliferation and represses myogenic differentiation by regulating Foxo4 and Mef2. J Cell Sci. 125, 5329-5337 (2012).
Grant, G. D. et al. Live-cell monitoring of periodic gene expression in synchronous human cells identifies Forkhead genes involved in cell cycle control. Mol Biol Cell. 23, 3079-3093 (2012).
Sukonina, V. et al. FOXK1 and FOXK2 regulate aerobic glycolysis. Nature. 566, 279-283 (2019).
Bowman, C. J., Ayer, D. E. & Dynlacht, B. D. Foxk proteins repress the initiation of starvation-induced atrophy and autophagy programs. Nat Cell Biol. 16, 1202-1214 (2014).
Hawke, T. J., Jiang, N. & Garry, D. J. Absence of p21CIP rescues myogenic progenitor cell proliferative and regenerative capacity in Foxk1 null mice. J Biol Chem. 278, 4015-4020 (2003).
Tang, M. et al. FOXK1 Participates in DNA Damage Response by Controlling 53BP1 Function. Cell Rep. 32, 108018 (2020).
Guo, X. & Wang, Y. LncRNA TMPO-AS1 promotes hepatocellular carcinoma cell proliferation, migration and invasion through sponging miR-329-3p to stimulate FOXK1-mediated AKT/mTOR signaling pathway. Cancer Med. 9, 5235-5246 (2020).
Peng, Y. et al. Direct regulation of FOXK1 by C-jun promotes proliferation, invasion and metastasis in gastric cancer cells. Cell Death Dis. 7, e2480 (2016).
Wu, M. et al. FOXK1 interaction with FHL2 promotes proliferation, invasion and metastasis in colorectal cancer. Oncogenesis. 5, e271 (2016).
Wencong, M. et al. FOXK1 Promotes Proliferation and Metastasis of Gallbladder Cancer by Activating AKT/mTOR Signaling Pathway. Front Oncol. 10, 545 (2020).
Chen, D. et al. FOXK1 plays an oncogenic role in the development of esophageal cancer. Biochem Biophys Res Commun. 494, 88-94 (2017).
Castro-Mondragon, J. A. et al. JASPAR 2022: the 9th release of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 50, D165-D173 (2022).
Huang, E. et al. CircRNA hsa_circ_0004771 promotes esophageal squamous cell cancer progression via miR-339-5p/CDC25A axis. Epigenomics. 12, 587-603 (2020).
Luo, A. et al. Exosome-derived miR-339-5p mediates radiosensitivity by targeting Cdc25A in locally advanced esophageal squamous cell carcinoma. Oncogene. 38, 4990-5006 (2019).
Fassl, A., Geng, Y. & Sicinski, P. CDK4 and CDK6 kinases: From basic science to cancer therapy. Science. 375, eabc1495 (2022).
Yang, Y. et al. CDK4/6 inhibitors: a novel strategy for tumor radiosensitization. J Exp Clin Cancer Res. 39, 188 (2020).
Benayoun, B. A., Caburet, S. & Veitia, R. A. Forkhead transcription factors: key players in health and disease. Trends Genet. 27, 224-232 (2011).
Xie, R. et al. RUFY3 interaction with FOXK1 promotes invasion and metastasis in colorectal cancer. Sci Rep. 7, 3709 (2017).
Meng, F. et al. SNHG1 knockdown upregulates miR-376a and downregulates FOXK1/Snail axis to prevent tumor growth and metastasis in HCC. Mol Ther Oncolytics. 21, 264-277 (2021).
Rogakou, E. P., Pilch, D. R., Orr, A. H., Ivanova, V. S. & Bonner, W. M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 273, 5858-5868 (1998).
Celeste, A. et al. Genomic instability in mice lacking histone H2AX. Science. 296, 922-927 (2002).
Bassing, C. H. et al. Increased ionizing radiation sensitivity and genomic instability in the absence of histone H2AX. Proc Natl Acad Sci U S A. 99, 8173-8178 (2002).
Kao, J. et al. gamma-H2AX as a therapeutic target for improving the efficacy of radiation therapy. Curr Cancer Drug Targets. 6, 197-205 (2006).
McIlwrath, A. J., Vasey, P. A., Ross, G. M. & Brown, R. Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer research. 54, 3718-3722 (1994).
Baro, M., Lopez Sambrooks, C., Quijano, A., Saltzman, W. M. & Contessa, J. Oligosaccharyltransferase Inhibition Reduces Receptor Tyrosine Kinase Activation and Enhances Glioma Radiosensitivity. Clin Cancer Res. 25, 784-795 (2019).
Hoffmann, I., Draetta, G. & Karsenti, E. Activation of the phosphatase activity of human cdc25A by a cdk2-cyclin E dependent phosphorylation at the G1/S transition. EMBO J. 13, 4302-4310 (1994).
Cangi, M. G. et al. Role of the Cdc25A phosphatase in human breast cancer. J Clin Invest. 106, 753-761 (2000).
Guo, P. et al. BPTF inhibition antagonizes colorectal cancer progression by transcriptionally inactivating Cdc25A. Redox Biol. 55, 102418 (2022).
Ding, F. N. et al. miR-122-5p modulates the radiosensitivity of cervical cancer cells by regulating cell division cycle 25A (CDC25A). FEBS Open Bio. 9, 1869-1879 (2019).
Li, H. et al. MiR-365 enhances the radiosensitivity of non-small cell lung cancer cells through targeting CDC25A. Biochem Biophys Res Commun. 512, 392-398 (2019).
Lim, S. & Kaldis, P. Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development. 140, 3079-3093 (2013).
Gao, X., Leone, G. W. & Wang, H. Cyclin D-CDK4/6 functions in cancer. Adv Cancer Res. 148, 147-169 (2020).
Patnaik, A. et al. Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors. Cancer Discov. 6, 740-753 (2016).
Kim, E. S. et al. Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study. Clin Cancer Res. 24, 5543-5551 (2018).
O'Leary, B., Finn, R. S. & Turner, N. C. Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol. 13, 417-430 (2016).
Shimura, T. et al. Targeting the AKT/GSK3beta/cyclin D1/Cdk4 survival signaling pathway for eradication of tumor radioresistance acquired by fractionated radiotherapy. Int J Radiat Oncol Biol Phys. 80, 540-548 (2011).
Deng, X. et al. miR-124 radiosensitizes human glioma cells by targeting CDK4. J Neurooncol. 114, 263-274 (2013).
Hagen, K. R. et al. Silencing CDK4 radiosensitizes breast cancer cells by promoting apoptosis. Cell Div. 8, 10 (2013).
Naz, S. et al. Abemaciclib, a Selective CDK4/6 Inhibitor, Enhances the Radiosensitivity of Non-Small Cell Lung Cancer In Vitro and In Vivo. Clin Cancer Res. 24, 3994-4005 (2018).
Hashizume, R. et al. Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth. Neuro Oncol. 18, 1519-1528 (2016).

No competing interests reported.

Download PDF

Journal Publication

published 12 May, 2023

Read the published version in Scientific Reports →

Editorial decision: Major revision
03 Mar, 2023
Reviews received at journal
17 Feb, 2023
Reviewers agreed at journal
09 Feb, 2023
Reviewers invited by journal
20 Jan, 2023
Editor assigned by journal
20 Jan, 2023
Editor invited by journal
15 Dec, 2022
Submission checks completed at journal
15 Dec, 2022
First submitted to journal
11 Dec, 2022

You are reading this latest preprint version

FOXK1 regulates malignant progression and radiosensitivity through direct transcriptional activation of CDC25A and CDK4 in esophageal squamous cell carcinoma

Status:

Journal Publication

Version 1

Abstract

Figures

Introduction

Results

Discussion

Materials And Methods

Ethics Declarations

Declarations

References

Additional Declarations

Supplementary Files

Status:

Journal Publication

Version 1